Cambridge Enterprise and the University of Cambridge Enterprise Fund, managed by Parkwalk, have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the Royal Botanic Gardens, Kew. Polypharmakos's mission is to screen natural-product sources of plant, fungal and insect origin for antimicrobially active substances with novel mechanisms of action and to develop them to address the emerging global antimicrobial resistance (AMR) crisis. Founded in 2016 by Dr John Normanton and Mr Tom Sopwith of ArgantriX Ltd., Polypharmakos arose from discussions with Prof Duncan Maskell (Marks & Spencer Professor of Farm Animal Health, Food Science and Food Safety) and Prof Monique Simmonds (Deputy Director of Science, Royal Botanic Gardens, Kew).
Pioneering research by Professor Paul Lewis of Swansea University's Medical School into one of the most common lung diseases in the UK, Chronic Obstructive Pulmonary Disease (COPD), has led to the development of a new technology that can quickly and easily diagnose and monitor the condition. This technology is now being taken forward commercially through the recently formed spin-out company PulmonIR Ltd.
The commercialisation of Swansea University's expertise is fundamental, both in terms of furthering the impact and reach of our research, and in supporting desperately needed economic regeneration within the region through the exchange of knowledge between industry and academia. Staff at the institution are actively encouraged to work alongside industry on projects, with support available to initially establish consultancy projects with external clients, and then to draft, review and negotiate contracts.
Haydale Graphene Industries plc (AIM: HAYD), the Group focused on enabling technology for the commercialisation of graphene and other nano materials, announced today it is exercising its rights under its existing pipeline agreement with Swansea University and Swansea Innovation Limited (together "Swansea") (the "Pipeline Agreement") to acquire a new invention (the "new invention").
Walking out of the Den back in 2009 with empty pockets and heads held high, Swansea University lecturers Dr David Williams and Dr John Dingley went on to partner with Timesco and successfully bring to market ShakerScope, a kinetically powered light source which enables essential medical instruments to be used in difficult locations where batteries and mains power supplies are not available.
This month Swansea Innovations launched its new website to promote the growing portfolio of technologies available for licensing and the high-tech, spin-out companies seeking industrial collaborations www.swanseainnovations.com. August has been a particularly busy month, with the launch of a new Swansea University Innovation Fund (SUIF) to accelerate the commercialisation of its academic research, a visit from a senior delegation from China’s Leshan Normal University, a week long campaign in the South Wales Evening Post promoting successful spin out activity and final preparations for the opening of the new Bay Campus in September.
A Swansea University based high-tech spin out company has just received accreditation under the Official Recognition of Efficacy Testing facilities or Organisations (ORETO) scheme for efficacy testing in Biologicals and Semiochemicals categories. It means Bionema Ltd now has a major advantage in a rapidly emerging market - opening up new International business opportunities.
On the 27th July 2015, Swansea University welcomed a senior delegation of 21 individuals to the Singleton campus from China’s Leshan Normal University (LSNU) on a week-long visit that concluded in the signing of a letter of intent between the two parties to forge closer working relationships with each other.
The Innovation Fund is the brain child of Dr Gerry Ronan, Head of Commercial Services at the University and will be overseen on a day to day basis by Dr Mark Bowman, Director of Arche Innovations Ltd. Dr Bowman has significant previous experience of seed stage venture capital investment in UK university spin-out companies.
Under the terms of the Agreement, Swansea will carry out a series of internally funded research projects to produce prototype applications using a range of Haydale materials. These materials can be the functionalised Haydale Graphene Nano Platelets (GNPs), and the Haydale conductive and insulating inks formulated by its collaboration partner the Welsh Centre for Printing and Coating (WCPC).
A Swansea University scheme to transform ideas into fully-backed businesses has produced success stories. InvestorG8 - a Welsh Government - funded 12-month pilot - is the first scheme of its kind in the UK to back academic ideas with capital, nurturing business ventures.
The Oxbridge Biotech Roundtable (OBR) and SR One, the venture capital arm of GlaxoSmithKline, have teamed up again for the OneStart competition - the largest biotech startup accelerator programme in the world - to offer young innovators from all disciplines the chance to win £100k with free lab space at Stevenage BioCiencia Catalyst near London.
Collaborative projects between students, businesses and local community. In-house projects or collaborations with other universities or businesses that create, manage or exploit intellectual property will all be considered.
3DS offer two new bioprinting systems. These machines are capable of depositing a range of biologically active and biologically compatible materials. 3DS is working on fabricating 3D transplantable bone and complex tissue constructs on demand.
Swansea Innovations spin-out and lighting manufacturer PhotonStar LED has conditionally raised £2.2m through a share placing. The group raised the proceeds by placing 31.4 million new shares of 1p each at a price of 7p per email@example.com